Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1349 TROCEPT mediated in-tumor delivery of immune checkpoint inhibitors reduces systemic toxicity risks and boosts immune activation
Compose a Response to This Article
Other responses
No responses have been published for this article.